Cancer risk was examined for breast, colorectal, lung, and prostate cancer.

Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.

These real-life data highlight dupilumab’s efficacy at 16 weeks, with the safety and effectiveness in children with atopic dermatitis continuing to 52 weeks.

The Breakthrough Therapy designation comes just months after positive phase 2 data for brelovitug were presented at AASLD The Liver Meeting in 2024.

The FDA approved esketamine (SPRAVATO) nasal spray as the first monotherapy for adults with TRD, showing rapid efficacy at 4 weeks.

Panelists discuss how the standard of care in atopic dermatitis (AD) has evolved with recent advances in treatment, highlighting the use of assessment tools and scoring systems in clinical practice, and compare real-world outcomes with those seen in clinical trials for AD treatments.

A study showed that vitamins, supplements, and antipsychotics were associated with an increased dementia risk.

The analysis of NHANES data revealed higher LE8 scores for cardiovascular health were linked to a decreased risk of MASLD.

A post-hoc analysis evaluated pooled data from 4 trials of pegloticase.

A new study found high concentrations of pollen from 3 species classes—ragweed, deciduous trees, and grass—are linked to increased chronic respiratory mortality.

Findings show differences in the clinicopathological characteristics and prognosis of patients with IgAN and nephrotic syndrome across renal pathologies.

In this summary, we highlight the latest issue of our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

This interview in the latest issue of The Respiratory Report features Stephen Schworer, Md, PhD, discussing the role of mucus plugging in severe asthma.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 18, 2025.

Exploring mucus plugging in severe asthma, focusing on small airway dysfunction, MUC5AC expression, and epithelial heterogeneity using advanced methods.

Joselyn Rojas-Quintero, MD, speaks about her team's current research into COPD treatment on this issue of The Respiratory Report.

The importance of AT2 cells in repairing injured alveoli and maintaining alveoli number and lumen size suggests that COPD therapies may be implemented to improve AT2 cell biology and/or increase AT2 cell numbers.

Panelists discuss how the NefIgArd study findings contribute valuable insights into the efficacy of emerging therapies for IgA nephropathy, emphasizing their role in reducing proteinuria and improving patient outcomes.

Abebaw Yohannes, MSc, PhD, speaks about his team’s pilot study designed to assess the use of duloxetine for patients with COPD and comorbid depression.

Panelists discuss how the PROTECT study’s results enhance the understanding of emerging therapies for IgA nephropathy, focusing on their potential to reduce proteinuria and modify disease progression.

Pilot study tests duloxetine’s feasibility for depression in COPD, examining patient/physician attitudes, treatment barriers, and therapy effects.

This summarizes the latest in our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

The RECEIVE study develops tools to standardize returning chest CT results in the Lung Health Cohort, improving engagement and ethical practices.

With a completed 12-week analysis, Outlook Therapeutics plans to resubmit the Biologics License Application for ONS-5010 in the first quarter of 2025.

This cohort study’s findings shed light on associated factors with acne relapse and retrial among individuals with acne who were treated with isotretinoin.